Alvotech secures $75M term loan
Analysis based on 9 articles · First reported Jul 01, 2026 · Last updated Jul 01, 2026
The market is likely to react positively to Alvogen's strengthened financial position, as the additional capital from the term loan facility and recent equity raise provides significant funding for its R&D pipeline and global product launches. This could lead to increased investor confidence in Alvogen's growth prospects and its ability to bring biosimilar medicines to market.
Alvogen, a global biotechnology company, secured an additional $75 million term loan facility led by GoldenTree Asset Management, bringing its total new capital access to $240 million, including a recent $165 million equity raise. This financing, which amends an existing credit agreement, will support Alvogen's growth strategy, including advancing its biosimilar pipeline, supporting product launches, and expanding global commercial operations. The term loan matures on December 31, 2027, and bears an interest rate of 12.50%. Róbert Wessman, founder and chairman of Alvogen, highlighted the strong support from investors and the company's recent milestones, such as FDA acceptance of a BLA for a biosimilar to Entyvio.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard